Health Care • Biotechnology: Pharmaceutical Preparations
$153.67 ▼ -1.07
(-0.69%)
MKT CAP: $6.23B • VOL: 114.9K
52W L $102 52W H $200
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
BLTE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $235.8M | $112.0M | $88.7M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$84.2M | -$40.0M | -$31.7M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$77.6M | -$36.1M | -$31.6M |
| EBITDA (Normalized) | -$84.2M | -$39.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$37.0M | -$29.2M | -$29.8M |
| Capital Expenditures (CapEx) | $71.0K | $116.0K | — |
| Free Cash Flow (FCF) | -$37.1M | -$29.4M | -$29.8M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -15.9% | -27.7% | — |
| Cash & Short-Term Equivalents | $352.9M | $31.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $770.5M | $145.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BLTE.